{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:50:07Z","timestamp":1789055407397,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NCI","award":["L30CA231689"],"award-info":[{"award-number":["L30CA231689"]}]},{"name":"NIH\/NCI","award":["P30CA023100"],"award-info":[{"award-number":["P30CA023100"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,12,27]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of solid tumors, including advanced gastric cancer (GC), has proven more challenging due to on-target off-tumor toxicities, poor tumor T-cell infiltration, inefficient CAR T-cell expansion, immunosuppressive tumor microenvironments, and demanding preconditioning regimens. We report the exceptional results of autologous Claudin18.2-targeted CAR T cells (CT041) in a patient with metastatic GC, who had progressed on four lines of combined systemic chemotherapy and immunotherapy. After two CT041 infusions, the patient had target lesion complete response and sustained an 8-month overall partial response with only minimal ascites. Moreover, tumor-informed circulating tumor DNA (ctDNA) reductions coincided with rapid CAR T-cell expansion and radiologic response. No severe toxicities occurred, and the patient\u2019s quality of life significantly improved. This experience supports targeting Claudin18.2-positive GC with CAR T-cell therapy and helps to validate ctDNA as a biomarker in CAR T-cell therapy.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical Insight:<\/jats:bold>\n                    Claudin18.2-targeted CAR T cells can safely provide complete objective and ctDNA response in salvage metastatic GC.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2023-007927","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:26:07Z","timestamp":1707135967000},"page":"e007927","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04404595","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gregory P","family":"Botta","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-504X","authenticated-orcid":false,"given":"Joseph","family":"Chao","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Sierra","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jia","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Y","family":"Hendrix","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy V","family":"Nolte Fong","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ween","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Heyman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Daniels","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-2494","authenticated-orcid":false,"given":"Dan","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Cellular and Regenerative Medicine, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghai","family":"Li","sequence":"additional","affiliation":[{"name":"CARsgen Therapeutics Corp, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, UCSD, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"2026052722201672000_12.2.e007927.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026052722201672000_12.2.e007927.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026052722201672000_12.2.e007927.3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14712598.2020.1819978","article-title":"Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors","volume":"21","author":"Date","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2026052722201672000_12.2.e007927.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259"},{"key":"2026052722201672000_12.2.e007927.5","unstructured":"Stomach cancer \u2014 cancer STAT facts. n.d. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"key":"2026052722201672000_12.2.e007927.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9378"},{"key":"2026052722201672000_12.2.e007927.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149"},{"key":"2026052722201672000_12.2.e007927.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"2026052722201672000_12.2.e007927.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"2026052722201672000_12.2.e007927.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.021"},{"key":"2026052722201672000_12.2.e007927.11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026052722201672000_12.2.e007927.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1547"},{"key":"2026052722201672000_12.2.e007927.13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy134"},{"key":"2026052722201672000_12.2.e007927.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2026052722201672000_12.2.e007927.15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"2026052722201672000_12.2.e007927.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2026052722201672000_12.2.e007927.17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"2026052722201672000_12.2.e007927.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1524","article-title":"Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer","volume":"32","author":"Huffman","year":"2021","journal-title":"Annals of Oncology"},{"key":"2026052722201672000_12.2.e007927.19","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1200\/JCO.2023.41.16_suppl.4053","article-title":"Circulating tumor DNA and association with CAR-T cell therapy response in gastric and pancreatic cancer patients","volume":"41","author":"Kubendran","year":"2023","journal-title":"JCO"},{"key":"2026052722201672000_12.2.e007927.20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127566","article-title":"Outpatient treatment with Lisocabtagene Maraleucel (Liso-Cel) in three ongoing clinical studies in Relapsed\/refractory (R\/R) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, and PILOT","volume":"134","author":"Bachier","year":"2019","journal-title":"Blood"},{"key":"2026052722201672000_12.2.e007927.21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12419"},{"key":"2026052722201672000_12.2.e007927.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0838-6"},{"key":"2026052722201672000_12.2.e007927.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"2026052722201672000_12.2.e007927.24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7"},{"key":"2026052722201672000_12.2.e007927.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2026052722201672000_12.2.e007927.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0432"},{"key":"2026052722201672000_12.2.e007927.27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.415"},{"key":"2026052722201672000_12.2.e007927.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"2026052722201672000_12.2.e007927.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:20:25Z","timestamp":1779945625000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jitc-2023-007927"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007927","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}